Click For Photo: https://i.insider.com/5e21eff83ac0c9230e61f61e?width=1200&format=jpeg&imgtype=.jpg
In a clinical trial conducted on 12,000 people, the US Food and Drug Administration found that people who took Belviq were diagnosed with cancer more than the people who didn't.
Belviq was first approved by the FDA in 2012 and works by making people feel fuller than they actually are.
FDA - Results - Trial - Patients - Health
The FDA is still evaluating the results of the trial and is advising patients and health professionals to weigh the potential health risks when taking Belviq.
A weight-loss drug is now tied to a "possible increased risk of cancer," according to the US Food and Drug Administration, which is advising patients and healthcare professionals to consider the potential risks when prescribing or taking Belviq or Belviq XR.
Drug - FDA - Works - Part - Brain
The drug, which was first approved by the FDA in 2012, works by targeting the part of the brain that regulates appetite, making the people who take the pill feel fuller than they actually are.
It was the first weight-loss drug the FDA had approved in 13 years for use in overweight and obese adults who had weight-related health conditions like hypertension or diabetes.
Findings - Result - Trial - Eisai - Inc
The recent findings came as a result of a clinical trial Eisai Inc., the manufacturer of Belviq, was required to conduct in order to maintain the FDA's stamp of approval. The randomized trial was conducted on 12,000 participants over five years and found that people taking lorcaserin, the generic name for Belviq, were diagnosed with cancer more often than people who weren't.
While the FDA isn't certain that Belviq causes cancer, the findings were enough to send out health alerts to the public. "We are continuing to evaluate the clinical trial results and will communicate our final conclusions and recommendations when we have completed our...
Wake Up To Breaking News!